Cihan Ay and Colleagues on Thromboembolism and Bleeding in Multiple Myeloma
RPTH Journal shared on LinkedIn:
”In newly diagnosed multiple myeloma patients on immunomodulatory drugs, VTE and bleeding risks remain high.
Direct oral anticoagulants showed a trend toward lower VTE vs aspirin/no prophylaxis, but bleeding rates were similar across all strategies.
Check out the full article for more details.”
Read the full article in RPTH.
Article: Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis
Authors: Lea Vospernik, Hermine Agis, Cihan Ay, Lina Rüsing, Heinz Gisslinger, Christina Brunbauer, Clara Sophie Michel, Ingrid Simonitsch-Klupp, Alexandra Kaider, Maria-Theresa Krauth, Julia Riedl
Stay updated on all scientific advances in the field of clotting disorders with Hemostasis Today.
-
Feb 19, 2026, 16:01Honoring Black Pioneers in Hematology During Black History Month – ASH
-
Feb 19, 2026, 15:16Irina Pahlevanyan: Global Leaders on Courage, Trust, and the True Purpose of Fundraising
-
Feb 19, 2026, 15:12Stéphanie Forté: Transition Readiness in Youth With Sickle Cell Disease
-
Feb 19, 2026, 15:08Tagreed Alkaltham: Strengthening Blood Inventory Governance Through RFID Technology
-
Feb 19, 2026, 14:59Başak Taburoğlu Yılmaz: Improving Diagnosis and Care for Women With Bleeding Disorders
-
Feb 19, 2026, 14:59Munira Borhany: Moving Beyond Stereotypes in the Diagnosis of Bleeding Disorders
-
Feb 19, 2026, 14:56Flora Peyvandi: Personalized VWF Dosing Revolutionizes Surgery in VWD
-
Feb 19, 2026, 14:54Michela Mazzon: The Molecular Trigger Behind the COVID19 Vaccines-Associated ITT
-
Feb 19, 2026, 14:42Luca Palombi: Real-Time Assessment of Venous Hemodynamics During Movement With DUS